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ABSTRAK
Latar belakang. Diabetes Melitus (DM) dan hipertensi merupakan penyakit yang saling berkaitan satu 
sama lain dan mempunyai predisposisi yang kuat terhadap kejadian aterosklerosis kardiovaskular. Kejadian 
hipertensi 2 kali lebih besar pada penderita DM dibandingkan non DM. Disfungsi endotel mendasari 
semua kejadian ini. Marker endotelial yaitu endotelin-1 diketahui dapat mempengaruhi tekanan darah. 
Tujuan. Penelitian ini bertujuan untuk mengetahui perbedaan rerata kadar endotelin-1 plasma pada 
wanita DM tipe 2 dengan dan tanpa hipertensi.
Metode. Penelitian dilakukan secara potong lintang. Penelitian dilakukan di poliklinik Endokrin dan 
Metabolik unit Penyakit Dalam RSUP Dr. Sardjito Yogyakarta mulai bulan Juli 2010 sampai jumlah sampel 
terpenuhi. Pemeriksaan kadar endotelin-1 diukur menggunakan metode ELISA sandwich. Karakteristik 
subyek penelitian disajikan dalam bentuk rerata dan simpang baku. Perbedaan antara dua kelompok 
dianalisa dengan uji t tidak berpasangan dan uji Mann-Whitney. Dianggap bermakna secara statistik bila 
p<0,05 dengan interval kepercayaan 95%. 
Hasil. Didapatkan rerata kadar endotelin-1 plasma pada wanita DM tipe 2 dengan hipertensi (n = 32) 
dan tanpa hipertensi (n = 32) berturut-turut 19,17 ± 7,53 ng/ml dan 13,75 ± 6,19 ng/dl, dan perbedaan 
ini bermakna secara statistik dengan p = 0,003 dengan RK 95% -8,87 sd -1,97.
Kesimpulan. Kadar endotelin-1 pada wanita DM tipe 2 dengan hipertensi lebih tinggi dibandingkan 
kelompok tanpa hipertensi
Kata kunci: endotelin-1, hipertensi, diabetes melitus tipe 2
ABSTRACT
Background. Diabetes and hypertension are related to each other and have a strong pre-disposition on 
the incidence of  atherosclerosis. The incidence of  hypertension 2 times greater in patients with DM  than 
non  DM. Endothelial dysfunction underlies these events. Endothelial markers, endothelin-1 is known 
to affect blood pressure.
Aim. The aim of  this study is to determine the difference plasma levels of  endothelin-1 in type 2 diabetes 
mellitus in women with and without hypertension.
Methods. The cross sectional design was conducted on women with type 2 diabetes mellitus with and 
without hypertension at metabolic and endocrinology clinic, Dr. Sardjito General Hospital Yogyakarta 
from July 2010 until the sample met the criterias. Subjects were divided into two groups, type 2 DM 
woman with hypertension groups and without hypertension. ELISA sandwich’s method was used to 
measure plasma levels of  endothelin-1. Characteristics of  the study are presented in the form of  mean 
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INTRODUCTION
Diabetes mellitus (DM) is a major threat 
to human health in the 21st century. In Asia-
Africa, especially the western Pacifi c region, 
estimated more than 30 million people suffer 
from diabetes. Databases from World Health 
Organization (WHO) in the year 2000 the 
diabetes frequencies over the age of  25 years 
amounted to 150 million people and by 2025 
that number estimated will be 300 million 
people.1.2
Hypertension and diabetes are related and 
have a strong predisposition to atherosclerotic 
cardiovascular events. The incidence of  
hypertension 2 times greater in patients with 
DM than non DM. Lifestyle and genetic factors 
plays an important role in hypertension and 
DM. About 35-75% cardiovascular and renal 
complication in patients with DM associated 
with hypertension. Its also contribute to 
the  incidence  of   retinopathy DM. For  all 
this  reason, hypertension  and DM should 
recognize and treated early and aggressively. 3.4
Chronic  d iabet ic  compl ica t ions 
constitute a group of  diseases responsible 
for substantial morbidity and mortality, 
thus preventing complications of  diabetes 
management is important. Several studies have 
identifi ed several factors that play key role in 
the pathogenesis of  diabetic complications 
such as protein kinase C (PKC) activation, 
non-enzymatic glycation, oxidative stress, and 
alterations in growth factor and vasoactive 
factor expression. Several of  these factors may 
subsequently lead to further endothelin (ET) 
activation in diabetic subjects.5
In some DM complications found 
increased levels of  ET-1. Endothelin-1 
levels affect blood pressure in various ways, 
increasing vasoconstriction, affecting the 
inflammatory response that contributes to 
vascular disorders remodeling and endothelial 
dysfunction.6   
Increased levels of  ET have an important 
role in the occurrence of  hypertension in 
diabetic subject. The changes in plasma 
levels of  ET can be found in several diseases 
associated with endothelial dysfunction, such 
as diabetes, hypertension and atherosclerosis.5
METHODS
The cross sectional design was conducted 
on women with type 2 diabetes mellitus with 
and without hypertension at metabolic and 
endocrinology clinic, Dr. Sardjito General 
Hospital Yogyakarta from July 2010 until 
the sample met the criterias. Subjects were 
divided into two groups, type 2 DM woman 
with hypertension groups and without 
hypertension. Inclusion criteria were women 
with type 2 diabetes who attend at the 
Endocrine Clinic Dr. Sardjito aged ≥ 22 
and standard deviations. The differences between groups were compared by student’s unpaired t-test an 
Mann Whitney test. The P value was considered signifi cant if  p<0.05 with 95% confi dence interval.
Results. In this research, the plasma levels of  endothelin-1 in in type 2 diabetes mellitus  in women  with 
hypertension  (n=32)  and  without  hypertension  (n=32) respectively 19.17±7.53 ng/ml and 13.75±6.19 
ng/dl, and this difference was stastistically signifi cant with p= 0.003 CI 95% -8.87 to -1.97.
Conclusion. Plasma levels of  endothelin-1 in type 2 diabetes woman with hypertension higher than 
without hypertension
Keywords:  endothelin-1,  hypertension,  diabetes mellitus type 2
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years to ≤ 60 years, signed informed consent. 
Exclusion criteria were  patients with chronic 
renal failure, chronic heart failure, malignancy, 
liver cirrhosis, sepsis, under steroid treatment, 
using hormonal contraceptives, pregnancy or 
breastfeeding.
Subjects who met the inclusion and 
exclusion criteria were invited to attend  the 
appointed  day. Inclusion and exclusion 
criteria established by anamnesis, physical 
examination and medical records.
The subjects were asked to perform  daily 
activities  and  have  diet  as usual. Hypertension 
medications commonly taken by subjects 
with hypertension are not taken within the 
previous 3 days. On the appointed day, the 
subject came in a fasting state for at least 8-10 
hours. The subject’s identity was recorded in 
the form of  research conducted anamnesis, 
physical examination (blood pressure, height, 
respiratory frequency, temperature, weight 
and waist circumference). We also put 
personal data in the form of  research, such as 
age, sex, history of  hypertension, the treatment 
of  hypertension, hypertension drug, and 
family history of  hypertension. The blood 
pressure was measured twice. After lying for 10 
minutes, and then performed taking as much 
as 20 ml of  venous blood for examination 
fasting glucose, postprandial glucose levels, 
lipid profile and levels of  endothelin-1. 
Examination of  blood samples carried out 
in biochemistry and laboratory in Medical 
Faculty of  Gadjah Mada University. Figure 1 
shown  the scheme of  this research.
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Figure 1. Research scheme
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Measurement
Levels of   endothelin-1  were  examined 
by  using Quantikinine  Human endothelin 
Immunoassay. Results are expressed in ng/ml.
Statistical Analysis
Characteristics of  the subjects are 
presented in the form of  mean and standard 
deviations. Mean difference between the levels 
of  an ET-1 group of  type 2 diabetes woman 
with and without hypertension were analyzed 
by independent t-test if  normally distributed 
or the non-parametric test Mann-Whitney U 
when the data are not normally distributed. 
Normality test using the Kolmogorov-Smirnov 
analysis (for samples > 50) or the Shapiro-Wilk 
analysis (for samples <50). Differences were 
considered statistically signifi cant, defi ned by 
p <0.05 with a confi dence interval (CI) 95%. 7
RESULTS
This study was conducted from July to 
December 2010. During the study period, we 
found 64 female subjects with type 2 diabetes 
who met the inclusion criteria consisting of  
32 subjects with hypertension (50%) and 32 
subjects without hypertension (50%). Baseline 
characteristics of  the subjects are shown in 
Table 1.
In this study, the median age of  women 
with type 2 diabetes was 55 years, 10 subjects 
with aged 41-50 years (16.13%) and aged 
between 51-60 years 52 subjects (83.87%), with 
median duration of  diabetes for 7 years. This 
suggests that increased endothelial damage as 
a result of  microvascular complications in line 
with the long-suffering DM.
In this study, the mean of  HbA1C levels 
about 8.19 ± 1.88%. In accordance with 
PERKENI8 consensus, HbA1C values in these 
subjects including poor control criteria. Overall 
the mean plasma levels of  ET-1 at 16.46 ± 7.37 
ng/dl. Normal endothelin levels is 1-2 pg/ml.9 
This is consistent with previous studies, the 
levels of  endothelin in patients with diabetes 
are higher than those who did not suffer from 
diabetes.
Table 1. Baseline characteristics of  the subjects
Variable Mean±SDMedian (Min-Max)
Frequencies
(%)
Hypertension status
• With hypertension
• Without hypertension
32 (50)
32 (50)
DM duration (years) 7(2-17)
Ages (years) 55 (44-59)
Height (m) 1.55±0.05
Weight (kg) 59.22±8.36
Body Mass Index (kg/m2) 24.65±3.27
Systolic blood pressure (mmHg) 130 (110-150)
Waist circumference (cm) 80 (70-90)
Fasting glucose (mg/dl) 131 (70-286)
Postprandial glucose (mg/dl) 177.33±38.66
HbA1C (%) 8.19±1.88
Endotelin-1 levels (ng/ml) 16.46±7.37
The Journal of  Internal Medicine, Acta Interna, Volume 5, Number 1, June 2015: 9-16
13 
Table 2 also shown the analysis of  the 
subject variable of  type 2 diabetes based on 
hypertension status. The mean age of  the 
subjects with type 2 diabetes with hypertension 
(55.53  ±  2.69) were older compared with 
type  2 diabetes without hypertension (52.56 
± 3.81), p = 0.002.
The mean body mass index (BMI) in 
subjects with type 2 diabetes with hypertension 
were signifi cantly higher than those with type 
2 diabetes without hypertension, respectively 
25.43 ± 2.61 kg/m2 and 22.86 ± 3.69 kg/
m2, and the Mann Whitney test statistically 
signifi cant (p = 0.034).
From blood pressure, the mean systolic 
and diastolic blood pressure in subjects with 
type 2 diabetes women with hypertension at 
137.50 ± 8.03 and 88.75 ± 3.36 mmHg, and 
this difference was statistically signifi cant (p 
= <0.001).
The mean fasting blood glucose in 
subjects with type 2 diabetes with hypertension 
than those without hypertension, respectively 
136.56 ± 43.56 mg/dl and 136.50 ± 30.52 
mg/dl. These results were not statistically 
significant. The mean of  the postprandial 
glucose levels in subjects with type 2 diabetes 
with hypertension also  lower  than  without 
hypertension with mean value of   each 167.25 
± 39.46 mg/dl and 187.41 ± 35.66. The mean 
of  HbA1c (%) was lower in the group with 
type 2 diabetes with hypertension (7.80 ± 
2.13%) compared with the group without 
hypertension (8.58 ± 1.53%).
In this study, the levels of  plasma 
endothelin-1 levels in patients with type 
2 diabetes with and without hypertension 
respectively 19.17 ± 7.53 ng/ml and 13.75 
± 6.19 ng/dl. The levels of  endothelin-1 in 
type 2 diabetes with hypertension than those 
with type 2 diabetes without hypertension is 
different and the difference was statistically 
signifi cant with p = 0.003 (CI 95% -8.87 to 
-1.97).
DISCUSSION
In this study, the subjects with age 51-60 
years are more than age 41-50 year groups. 
These results are consistent with studies that 
reported by Yang et al10 and Ferrara et al11 
the prevalence of  diabetes increases with age 
(20-39 years age group increased 3.2%, the 
group increased 11.5% 40-59 years, and ≥ 60 
years increased 20.4%). In older people there 
Table 2. Mean difference variables of  type 2 DM subjects by hypertension status
Variable Type 2 DM With Hypertension
Type 2 DM
Without Hypertension P IK 95%
Age (years) 55.53 ± 2.69 52.56 ± 3.81 0.002*
Height (m) 1.56±0.04 1.55±0.06 0.335 -0.03 sd 0.01
Weight (kg) 61.81±6.72 56.63±9.12 0.012 -9.19 sd -1.19
Body Mass Index (kg/m2) 25.43±2.61 22.86±3.69 0.034*
Systolic blood Pressure (mmHg) 137.50±8.03 118.75±7.93 <0.001*
Diastolic blood pressure (mmHg) 88.75±3.36 74.69±5.07 <0.001*
Fasting glucose (mg/dl) 136.56±43.56 136.50±30.52 <0.545*
Postprandial glucose (mg/dl) 167.25±39.46 187.41±35.66 0.036 1.36 sd 38.95
HbA1C (%) 7.80±2.13 8.58±1.53 0.09 -0.15 sd 1.69
Endothelin-1 levels (ng/ml) 19.17±7.53 13.75±6.19 0.003 -8.87 sd -1.97
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is a decrease in physical activity and muscle 
mass and increased body fat that contributes 
to worsening insulin sensitivity with age in 
both men and women. Type 2 diabetes is 
usually diagnosed in people aged 40 years or 
older. AkG  et al12  showed that patients with 
diabetes duration > 10 years had higher levels 
of  ET-1 than patients with diabetes duration 
<10 years (p = 0.02). In this study, the median 
duration suffered from diabetes is 7 years. This 
suggests that increased endothelial damage as 
a result of  microvascular complications in line 
with the long-suffering DM.
At baseline characteristics, the mean 
body mass index (BMI) of  the subjects is 24.65 
± 3.27 kg/m2. Based on WHO13 criteria for the 
Asia, it is include pre-classifi cation of  obesity 
(BMI 23.0 to 24.9 kg/m2). The increased risk 
was further increased comorbid in individuals 
with increased waist circumference. Based on 
PERKENI8, the mean of  BMI in the subjects 
of  this study included a moderate diabetes 
control (BMI 23-25 kg/m2).
The mean of  HbA1C levels in this study 
is 8.19 ± 1.88%. In accordance with PERKENI8, 
HbA1C levels in these studies, including poor 
control criteria. This is consistent with Sanchez 
et al14 study, that showed a correlation between 
the levels of  ET-1 with glycemic control. Diabetic 
patients with poor glycemic control showed 
elevated  levels  of   ET-1  were  higher  than 
those  with  good glycemic control (13.03 ± 7.57 
v.s. 7.64 ± 1.40 pg/ml, p <0.01).
In this study, overall the mean plasma 
levels of  ET-1 at 16.46 ± 7.37 ng/dl. This is 
consistent with previous studies; the levels of  
endothelin in patients with diabetes are higher 
than those who did not suffer from diabetes.
The study involved two groups of  
female subjects with type 2 diabetes were 
divided based on the status of  hypertension, 
the hypertensive group included 32 subjects 
(50%) and without hypertension were 32 
subjects (50%). The relationship between 
hypertension and diabetes is very strong 
because there are several criteria that often 
exist in patients with hypertension such as 
the increased of  blood pressure, obesity, 
dyslipidemia, and increased of  blood glucose. 
Hypertension in diabetes incidence associated 
with major cardiovascular diseases. Incidence 
of  hypertension are 2 times greater in patients 
with DM than non DM. The presence of  
hypertension in patients with diabetes will 
accelerate the microvascular complications, 
and increased the mortality of  4 to 5 times.15
From the blood pressure parameters, we 
have known the mean systolic and diastolic 
blood pressure in subjects with type 2 diabetes 
women with hypertension at 137.50 ± 8.03 
and 88.75 ± 3.36 mmHg. These results are 
consistent with the Aziza et al6, which states 
that the expression of  ET-1 in hypertension 
than those with pre-hypertension and 
ET-1 in the pre-hypertension higher than 
normotensive (p =0.007). DM is closely 
linked to hypertension, about 75% of  diabetic 
patients develop into hypertension. Some of  
the mechanisms leading to the occurrence 
of  hypertension in patients with diabetes 
include activation of  the renin-angiotensin- 
aldosterone system, presence of  intravascular 
volume expansion caused by hyperglycemia, 
decreased   baroreceptor   response,   autonomic 
dysfunction, endothelial dysfunction and 
oxidative stress vascular. 16
The levels of  endothelin-1 in patients 
with type 2 diabetes with and without 
hypertension respectively 19.17 ± 7.53 ng/ml 
and 13.75 ± 6.19 ng/dl. Levels of  endothelin-1 
in type 2 diabetes with hypertension than those 
with type 2 diabetes without hypertension are 
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higher and this difference was statistically 
signifi cant with p = 0.003 (CI 95% -8.87 to 
-1.97). These results are consistent with Singh et 
al17 study, reported a signifi cant relationship 
between levels of  ET-1 and hypertension, 
elevated levels of  endothelin in patients with 
type 2 diabetes with hypertension compared 
with controls with average levels of  endothelin 
respectively 4.94 ± 1.42 and 4.21 ± 0.84 pg/
ml (p = 0.046).
Another study conducted by Skalska, et 
al1,8 reported in subjects with hypertension 
the levels of  ET-1 were higher (1.35 ± 0.51 
VS1, 12 ± 0.46 pg/ml, p = 0.04) compared 
controls. ET-1 levels are increased is associated 
with low plasma antioxidant status, oxidative 
stress resulting from an increase in diabetes 
and hypertension.
Schneider et al19 also reported patients 
with diabetes or hypertension have elevated 
levels of  ET-1 compared with controls, but 
the elevated levels of  ET-1 do not cause 
hypertension in diabetes. These findings 
suggest that plasma levels of  ET-1 are not 
a marker of  endothelial dysfunction, but 
the changes of  plasma levels of  ET-1 may 
precede vascular complications associated 
with hypertension and diabetes.
In this research, we have done in women 
with type 2 diabetes with and without 
hypertension, between the two groups there 
are signifi cant differences on several variables, 
age, body mass index, postprandial blood 
glucose and ET-1 levels.
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